Novo Giuseppina, Pugliesi Marinella, Visconti Claudia, Spatafora Pietro, Fiore Marianna, Di Miceli Riccardo, Guarneri Francesco Paolo, Vitale Giustina, Novo Salvatore
Chair of Cardiovascular Diseases, Center for the early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention of Cardiovascular Diseases, Division of Cardiology, University Hospital 'Paolo Giaccone', University of Palermo, Italy.
J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):110-4. doi: 10.2459/JCM.0b013e3283638164.
The aim of our study was to evaluate the relationship between insulin resistance and the detection of precocious echocardiographic signs of heart failure in patients with cardiovascular risk factors.
We enrolled 34 consecutive patients with cardiovascular risk factors. All patients underwent coronary angiography, echocardiography, and laboratory tests. Exclusion criteria were diabetes (fasting glucose greater than 126 mg/dl or treatment with insulin or oral hypoglycemic agents), coronary artery disease, creatinine above 1.5 mg/dl, left-ventricular hypertrophy, valvular heart disease, ejection fraction below 50%, atrial fibrillation, or other severe arrhythmia. The presence of insulin resistance was assessed by using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Ventricular function was investigated by echocardiography.
Distinguishing patients with insulin resistance, based on the median value of HOMA-IR (<4.06 and >4.06), we observed that in the group with higher levels of HOMA-IR, there were echocardiographic signs of subclinical ventricular dysfunction statistically more frequent (E/A in group with HOMA <4.06: 1.159 + 0.33 vs. group with HOMA >4.06: 0.87 + 0.29, P = 0.0136; E/E': 6.42 + 4 vs. 15.52 + 3.26, P = 0.001; Tei index: 0.393 + 0.088 vs. 0.489 + 0.079, P = 0.0029; S wave: 0112 + 0.015 vs. 0.114 + 0.027, P = 0.0001; ejection fraction 59.11 + 4.75 vs. 58.88 + 6.81, P = 0.9078). Grade II diastolic dysfunction was observed in 5 patients, grade I in 12 patients, and 17 patients had normal diastolic function. On multivariate analysis, HOMA-IR (P = 0.0092), hypertension (P = 0.0287), waist circumference (P = 0.0009), high-density lipoprotein (P = 0.0004), and fasting blood glucose (P = 0.0003) were variables independently associated with diastolic dysfunction. On analysis of covariance, we found that the variables that influence diastolic dysfunction are HOMA-IR, waist circumference, BMI, and age, and that the only variable that influences Tei index is HOMA-IR.
Insulin resistance is frequently associated with subclinical left-ventricular dysfunction. Patients with cardiovascular risk factors and increased HOMA-IR levels, although without diabetes mellitus, overt coronary artery disease, or hypertensive cardiomyopathy, may represent a target population for screening programs, recommended changes in lifestyle, and possibly the use of pharmacological interventions to prevent the onset of heart failure.
本研究旨在评估心血管危险因素患者胰岛素抵抗与早期超声心动图心力衰竭征象检测之间的关系。
我们连续纳入了34例有心血管危险因素的患者。所有患者均接受了冠状动脉造影、超声心动图检查和实验室检测。排除标准为糖尿病(空腹血糖大于126mg/dl或使用胰岛素或口服降糖药治疗)、冠状动脉疾病、肌酐高于1.5mg/dl、左心室肥厚、瓣膜性心脏病、射血分数低于50%、心房颤动或其他严重心律失常。采用胰岛素抵抗稳态模型评估(HOMA-IR)来评估胰岛素抵抗的存在。通过超声心动图研究心室功能。
根据HOMA-IR的中位数(<4.06和>4.06)区分胰岛素抵抗患者,我们观察到在HOMA-IR水平较高的组中,亚临床心室功能障碍的超声心动图征象在统计学上更频繁出现(HOMA<4.06组的E/A:1.159±0.33 vs. HOMA>4.06组:0.87±0.29,P = 0.0136;E/E':6.42±4 vs. 15.52±3.26,P = 0.001;Tei指数:0.393±0.088 vs. 0.489±0.079,P = 0.0029;S波:0.112±0.015 vs. 0.114±0.027,P = 0.0001;射血分数:(59.11±4.75)vs.(58.88±6.81),P = 0.9078)。5例患者出现II级舒张功能障碍,12例患者出现I级舒张功能障碍,17例患者舒张功能正常。多因素分析显示,HOMA-IR(P = 0.0092)、高血压(P = 0.0287)、腰围(P = 0.0009)、高密度脂蛋白(P = 0.0004)和空腹血糖(P = 0.0003)是与舒张功能障碍独立相关的变量。协方差分析发现,影响舒张功能障碍的变量是HOMA-IR、腰围、BMI和年龄,而影响Tei指数的唯一变量是HOMA-IR。
胰岛素抵抗常与亚临床左心室功能障碍相关。有心血管危险因素且HOMA-IR水平升高的患者,尽管没有糖尿病、明显的冠状动脉疾病或高血压性心肌病,但可能是筛查项目、推荐生活方式改变以及可能使用药物干预以预防心力衰竭发生的目标人群。